Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)

Summary

Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other newer agents. Here we review the mechanisms of action, pharmacological properties and side effects of parenteral anticoagulants used in the management of coronary heart disease treated with or without percutaneous coronary interventions, cardioversion for atrial fibrillation, and prosthetic heart valves and valve repair. Using an evidence-based approach, we describe the results of completed clinical trials, highlight ongoing research with currently available agents, and recommend therapeutic options for specific heart diseases.

Keywords

Parenteral anticoagulants - coagulation - heart disease - coronary heart disease - heart failure - atrial fibrillation

^* Coordinating Committee Member

^** Task Force Member

• References

• 1 Patrono C, Andreotti F, Arnesen H. et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Expert position paper on the use of anti-platelet agents by the Task Force of the European Society of Cardiology on the use of antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932.
• 2 De Caterina R, Husted S, Wallentin L. et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28: 880-913.
• 3 De Caterina R, Husted S, Wallentin L. et al. ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease - Position paper: General Mechanisms of Coagulation and Targets of Anticoagulants. Thromb Haemost 2013; 109: 569-579.
• 4 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 21: 2719-2747.
• 5 Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl. 02) S5-S12.
• 6 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
• 7 Tollefsen DM, Majerus DW, Blank MK, Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169.
• 8 Barrow RT, Parker ET, Krishnaswamy S. et al. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-26800.
• 9 Sheehan JP, Kobbervig CE, Kirkpatrick HM. Heparin inhibits the intrinsic ten-ase complex by interacting with an exosite on factor IXa. Biochemistry 2003; 42: 11316-11325.
• 10 Collet J-P, Montalescot G, Golmard JL. et al. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am Heart J 2004; 147: 655-661.
• 11 Antman EM. The search for replacements for unfractionated heparin. Circulation 2001; 103: 2310-2314.
• 12 Rao LV, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-2607.
• 13 Dawes J, Bara L, Billaud E. et al. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfraction-ated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122.
• 14 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114.
• 15 Raschke RA, Reilly BM, Guidry JR. et al. The weight-based heparin dosing no-mogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-881.
• 16 Garcia DA, Baglin TP, Weitz JI. et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e24S-e43S.
• 17 Basu D, Gallus A, Hirsh J. et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327.
• 18 Bates SM, Weitz JI, Johnston M. et al. Use of a fixed activated partial thrombo-plastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001; 161: 385-391.
• 19 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e495S-e530S.
• 20 Chong BH, Isaacs A. Heparin-induced thrombocytopenia: what clinicians need to know. Thromb Haemost 2009; 101: 279-283.
• 21 Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006; 118: 165-176.
• 22 Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
• 23 Weitz JI. Low-molecular-weight heparins. 1997; N Engl J Med 1997; 337: 688-699. correction 1997; 337: 567.
• 24 Montalescot G, Collet JP, Lison L. et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-114.
• 25 Montalescot G, Philippe F, Ankri A. et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-299.
• 26 Spinler SA, Inverso SM, Cohen M. et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41.
• 27 Goudable C, Saivin S, Houin G. et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991; 59: 543-545.
• 28 Becker RC, Spencer FA, Gibson M. et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacody-namics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143: 753-759.
• 29 Cestac P, Bagheri H, Lapeyre-Mestre M. et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26: 197-207.
• 30 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 31 Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 09: 122-125.
• 32 Pettilä V, Leinonen P, Markkola A. et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-186.
• 33 Wawrzyńska L, Tomkowski WZ, Przedlacki J. et al. Changes in bone density during long-term administration of low-molecular-weight heparins or aceno-coumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-67.
• 34 Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Pract Res Clin Haematol 2004; 17: 89-104.
• 35 Sharma T, Mehta P, Gajra A. Update on fondaparinux: role in management of thromboembolic and acute coronary events. Cardiovasc Hematol Agents Med Chem 2010; 08: 96-103.
• 36 Petitou M, Nancy-Portebois V, Dubreucq G. et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009; 102: 804-810.
• 37 Lisman T, Bijsterveld NR, Adelmeijer J. et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 01: 2368-2373.
• 38 Linkins L-A, Julian JA, Rischke J. et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002; 107: 241-244.
• 39 Lobo B, Finch C, Howard A. et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
• 40 Handschin AE, Trentz OA, Hoerstrup SP. et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-183.
• 41 Matziolis G, Perka C, Disch A. et al. Effects of fondaparinux compared with dal-teparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 2003; 73: 370-379.
• 42 Herbert JM, Hérault JP, Bernat A. et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-4205.
• 43 Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009; 102: 811-815.
• 44 Bousser MG, Bouthier J, Buller HR. et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371: 315-321.
• 45 Büller HR, Gallus AS, Pillion G. et al. Enoxaparin followed by once-weekly idra-biotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379: 123-129.
• 46 Desconclois C, Ract C, Boutekedjiret T. et al. Heparin-induced thrombocytope-nia: successful biological and clinical management with lepirudin despite severe renal impairment. Thromb Haemost 2011; 105: 568-569.
• 47 Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
• 48 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
• 49 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
• 50 Théroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
• 51 Cohen M, Adams PC, Hawkins L. et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol 1990; 66: 1287-1292.
• 52 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830.
• 53 Cohen M, Adams PC, Parry G. et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81-88.
• 54 Holdright D, Patel D, Cunningham D. et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischaemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39-45.
• 55 Gurfinkel EP, Manos EJ, Mejail RI. et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischaemia. J Am Coll Cardiol 1995; 26: 313-318.
• 56 Oler A, Whooley MA, Oler J. et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. J Am Med Assoc 1996; 276: 811-815.
• 57 Wallentin L, Ohlsson J, Swahn E. Low-molecular-weight heparin during instability in coronary artery disease: Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Lancet 1996; 347: 561-568.
• 58 Eikelboom JW, Anand SS, Malmberg K. et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-1942.
• 59 FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-707.
• 60 Camm AJ, Kirchhof P, Lip GYH. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
• 61 Bonow RO, Carabello BA, Chatterjee K. et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-661.
• 62 Vahanian A, Alfieri O, Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451-2496.
• 63 Navarese EP, De Luca G, Castriota F. et al. Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011; 09: 1902-1915.
• 64 The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 358: 605-613.
• 65 Montalescot G, Zeymer U, Silvain J. et al. Intravenous enoxaparin or unfraction-ated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011; 378: 693-703.
• 66 Wallentin L, Goldstein P, Armstrong PW. et al. Efficacy and safety of tenecte-plase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108: 135-142.
• 67 Armstrong PW, Chang WC, Wallentin L. et al. Efficacy and safety of unfraction-ated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and −3 PLUS data. Can Med Assoc J 2006; 174: 1421-1426.
• 68 Eikelboom JW, Quinlan DJ, Mehta SR. et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005; 112: 3855-3867.
• 69 Antman EM, Morrow DA, McCabe CH. et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-1488.
• 70 Sleight P, Eikelboom JW, Bassand JP. Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. N Engl J Med 2006; 354: 2830-2831. author reply 2831-2832.
• 71 Klein W, Buchwald A, Hillis SE. et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin In unstable Coronary artery disease Study (FRIC). Circulation 1997; 96: 61-68.
• 72 Antman EM, Cohen M, Radley D. et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B–ESSENCE meta-analysis. Circulation 1999; 100: 1602-1608.
• 73 Cohen M, Demers C, Gurfinkel EP. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997; 337: 447-452.
• 74 Antman EM, McCabe CH, Gurfinkel EP. et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-1601.
• 75 The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999; 20: 1553-1562.
• 76 Goodman SG, Fitchett D, Armstrong PW. et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-244.
• 77 Ferguson JJ, Califf RM, Antman EM. et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. J Am Med Assoc 2004; 292: 45-54.
• 78 Blazing MA, de Lemos JA, White HD. et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. J Am Med Assoc 2004; 292: 55-64.
• 79 Cohen M, Théroux P, Borzak S. et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. Am Heart J 2002; 144: 470-477.
• 80 Petersen JL, Mahaffey KW, Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. J Am Med Assoc 2004; 292: 89-96.
• 81 Kolh P, Wijns W, Danchin N. et al. Guidelines on myocardial revascularisation. Eur J Cardiothorac Surg 2010; 38 (Suppl. 01) S1-S52.
• 82 Collet J-P, Montalescot G, Lison L. et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103: 658-663.
• 83 Ferguson JJ, Antman EM, Bates ER. et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003; 146: 628-634.
• 84 Kereiakes DJ, Kleiman NS, Fry E. et al. Dalteparin in combination with abcixi-mab during percutaneous coronary intervention. Am Heart J 2001; 141: 348-352.
• 85 Rao SV, Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. Circul Cardiovasc Interv 2010; 03: 80-88.
• 86 Schulz S, Mehilli J, Neumann FJ. et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31: 2482-2491.
• 87 Montalescot G, White HD, Gallo R. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-1017.
• 88 Mehta SR, Steg PG, Granger CB. et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111: 1390-1397.
• 89 Yusuf S, Mehta SR, Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1530.
• 90 Yusuf S, Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enox-aparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
• 91 Simoons ML, Bobbink IWG, Boland J. et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the PENTasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43: 2183-2190.
• 92 Coussement PK, Bassand J-P, Convens C. et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716-1724.
• 93 Vuillemenot A, Schiele F, Meneveau N. et al. Efficacy of a synthetic pentasac-charide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81: 214-220.
• 94 Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral antico-agulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Ir-besartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
• 95 Steg PG, Jolly SS, Mehta SR. et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. J Am Med Assoc 2010; 304: 1339-1349.
• 96 Hamm CW, Bassand JP, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
• 97 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
• 98 Stone GW, Witzenbichler B, Guagliumi G. et al. Heparin plus a glycoprotein IIb/ IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-2204.
• 99 Stellbrink C, Nixdorff U, Hofmann T. et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003.
• 100 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
• 101 Nikolsky E, Stone GW. Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. Future Cardiol 2007; 03: 345-364.
• 102 Kastrati A, Neumann FJ, Schulz S. et al. Abciximab and heparin versus bival-irudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365: 1980-1989.
• 103 Borentain M, Montalescot G, Bouzamondo A. et al. Low-molecular-weight heparin vs unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 2005; 65: 212-221.